GlpBio

c-Kit

c-Kit(肥大/干细胞生长因子受体)

C-kit is a type of receptor tyrosine kinase and a type of tumor marker, also called CD117 and stem cell factor receptor.

c-Kit 相关产品(57)

  • GC11171 structure
    GC11171DCC-2618
    CAS: 1225278-16-9
    纯度: >98.50%

    A dual inhibitor of c-Kit and c-MET

  • GC13012 structure
    GC13012Motesanib
    CAS: 453562-69-1
    纯度: >99.50% / >98.00%

    Motesanib (AMG 706) 是一种有效的 ATP 竞争性 VEGFR1/2/3 抑制剂，IC50 分别为 2 nM/3 nM/6 nM，对 Kit 具有相似的活性，对 VEGFR 的选择性比对 VEGFR 的选择性高约 10 倍PDGFR 和 Ret。

  • GC16391 structure
    GC16391Amuvatinib (MP-470, HPK 56)
    CAS: 850879-09-3
    纯度: >98.00%

    A multi-targeted RTK inhibitor

  • GC10719 structure
    GC10719Toceranib
    CAS: 356068-94-5

    A multi-targeted receptor tyrosine kinase inhibitor

  • GC10914 structure
    GC10914AST 487
    CAS: 630124-46-8
    纯度: >99.00%

    A multi-kinase inhibitor

  • GC11336 structure
    GC11336Motesanib Diphosphate (AMG-706)
    CAS: 857876-30-3
    纯度: >99.50%

    A multikinase inhibitor

  • GC11759 structure
    GC11759Imatinib Mesylate (STI571)
    CAS: 220127-57-1
    纯度: >99.50%

    Imatinib Mesylate (STI571)是一种口服生物有效的多靶点抑制剂，对Bcr-Abl，c-Kit和PDGFR的IC 50 分别为0.6μM，0.1μM 和0.1μM。

  • GC11763 structure
    GC11763Telatinib (BAY 57-9352)
    CAS: 332012-40-5
    纯度: >98.50%

    A multi-kinase inhibitor

  • GC12222 structure
    GC12222Pexidartinib (PLX3397)
    CAS: 1029044-16-3
    纯度: >98.00%

    Pexidartinib(PLX3397) 是一种口服小分子酪氨酸激酶抑制剂，对集落刺激因子 1(CSF1) 受体 (IC50=20nM)、KIT 原癌基因受体酪氨酸激酶 (KIT)(IC50 = 10nM) 和类 FMS 酪氨酸激酶 3Pexidartinib 在体外是一种比伊马替尼更强的 KIT 抑制剂。

  • GC12730 structure
    GC12730Pazopanib Hydrochloride
    CAS: 635702-64-6
    纯度: >99.50%

    A multi-kinase inhibitor

  • GC13264 structure
    GC13264Ki20227
    CAS: 623142-96-1
    纯度: >98.00%

    A c-Fms kinase inhibitor

  • GC13410 structure
    GC13410Masitinib (AB1010)
    CAS: 790299-79-5
    纯度: >99.50%

    An inhibitor of c-Kit

  • GC13547 structure
    GC13547Dovitinib (TKI-258, CHIR-258)
    CAS: 405169-16-6
    纯度: >98.00%

    Dovitinib (TKI-258, CHIR-258)是一种高效，具有口服活性和安全药代动力学特性的小分子多激酶抑制剂，作用于FLT3、KIT和FGFR等靶点，IC 50 值分别为1、2和8-9nM。

  • GC13914 structure
    GC13914Flumatinib mesylate
    CAS: 895519-91-2
    纯度: >99.50%

    A Bcr-Abl inhibitor

  • GC13961 structure
    GC13961ISCK03
    CAS: 945526-43-2
    纯度: >99.00%

    An inhibitor of SCF/c-kit signaling

  • GC14292 structure
    GC14292Apatinib Mesylate
    CAS: 811803-05-1
    纯度: >98.00%

    A selective VEGFR2 inhibitor

  • GC14315 structure
    GC14315SU14813 maleate
    CAS: 849643-15-8
    纯度: >99.50%

    A dual VEGFR and PDGFR family kinase inhibitor

  • GC14733 structure
    GC14733SU14813
    CAS: 627908-92-3
    纯度: >98.50%

    A dual VEGFR and PDGFR family kinase inhibitor

  • GC14957 structure
    GC14957OSI-930
    CAS: 728033-96-3
    纯度: >98.00%

    A dual inhibitor of Kit and VEGFR2

  • GC15075 structure
    GC15075PLX647
    CAS: 873786-09-5
    纯度: >99.00%

    A dual inhibitor of FMS and KIT

  • GC15254 structure
    GC15254Tandutinib (MLN518)
    CAS: 387867-13-2
    纯度: >99.00%

    An antagonist of PDGFRβ, FLT3, and c-Kit

  • GC15454 structure
    GC15454Lenvatinib (E7080)
    CAS: 417716-92-8
    纯度: >99.50%

    E7080，称为乐伐替尼，是一种口服多靶点酪氨酸激酶抑制剂，包括 VEGF、FGF 和 SCF 受体，已被证明可以提高放射性碘难治性甲状腺癌患者的生存率。

  • GC15779 structure
    GC15779Cabozantinib (XL184, BMS-907351)
    CAS: 849217-68-1
    纯度: >99.50%

    Cabozantinib (XL184,BMS-907351) 是一种新型 MET 和 VEGFR2 抑制剂，可同时抑制转移、血管生成和肿瘤生长。

  • GC16327 structure
    GC16327Pazopanib (GW-786034)
    CAS: 444731-52-6
    纯度: >99.50%

    A multi-kinase inhibitor